Sonoma Pharmaceuticals
SNOA
15 hedge funds and large institutions have $159K invested in Sonoma Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0.06% less ownership
Funds ownership: 0.29% → 0.23% (-0.06%)
6% less funds holding
Funds holding: 16 → 15 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
60% less capital invested
Capital invested by funds: $396K → $159K (-$237K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$29.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.59K |
| 3 |
NC
NewSquare Capital
Newtown Square,
Pennsylvania
|
+$36 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$72K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$39K |
| 3 |
HFS
HBC Financial Services
Seattle,
Washington
|
-$17K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.59K |
| 5 |
Renaissance Technologies
New York
|
-$1.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $83K | -$1.6K | -45 | -1% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $41K | -$214 | -6 | -0.3% |
|
|
3
Millennium Management
New York
| $19K | +$29.5K | +830 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $9K | +$5.59K | +157 | +64% |
|
|
5
UBS Group
Zurich,
Switzerland
| $3.28K | -$4.59K | -129 | -47% |
|
6
BlackRock
New York
| $3.22K | – | – | – |
|
7
US Bancorp
Minneapolis,
Minnesota
| $560 | – | – | – |
|
8
Morgan Stanley
New York
| $96 | – | – | – |
|
|
AF
9
Allworth Financial
Folsom,
California
| $73 | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $49 | – | – | – |
|
|
GI
11
Gradient Investments
Arden Hills,
Minnesota
| $35 | – | – | – |
|
12
Wells Fargo
San Francisco,
California
| $24 | – | – | – |
|
|
NC
13
NewSquare Capital
Newtown Square,
Pennsylvania
| $11 | +$36 | +1 | New |
|
|
14
Vanguard Group
Malvern,
Pennsylvania
| – | -$72K | -1,701 | Closed |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$39K | -918 | Closed |
|
|
HFS
16
HBC Financial Services
Seattle,
Washington
| – | -$17K | -10 | Closed |
|
SNOA Hedge Fund Activity: Q4 2022 in Review
15 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2022, worth a combined $159K — down 60% from $396K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SNOA and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $29.5K. The largest seller was Vanguard Group, exiting entirely with an estimated $72K sold.
- 15 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2022, down from 16 in Q3 2022.
- Funds reported $159K of Sonoma Pharmaceuticals stock for Q4 2022, down 60% quarter-over-quarter.
- 2 funds opened new Sonoma Pharmaceuticals positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest Sonoma Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $29.5K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2022 was Vanguard Group, an estimated $72K sold.
Based on aggregated 13F filings for Q4 2022.